首页/数据集/Summary of high-quality non-randomized studies comparing ranibizumab with bevacizumab.

Summary of high-quality non-randomized studies comparing ranibizumab with bevacizumab.

NIAID Data Ecosystem2026-03-09 收录

数据链接：

https://figshare.com/articles/dataset/_Summary_of_high_quality_non_randomized_studies_comparing_ranibizumab_with_bevacizumab_/1207168 数据链接链接失效反馈

官方服务：

资源简介：

Summary of high-quality non-randomized studies comparing ranibizumab with bevacizumab.

应用场景：

创建时间：

2014-10-16

视网膜静脉阻塞

抗VEGF药物

Background: This meta-analysis aims to compare the efficacy and safety of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents and intravitreal steroids for the treatment of macular

NIAID Data Ecosystem90

Model selection: comparison of the total residual deviance and DIC for Bayesian network meta-analyses with fixed or random treatment effects and baseline BCVA and/or CRT as covariates.

抗VEGF药物

视网膜疾病治疗

*Relative treatment effect for ranibizumab 0.5 mg PRN versus aflibercept 2.0 mg bi-monthly. BCVA, best-corrected visual acuity; CrI, credible interval; CRT, central retinal thickness; DIC, deviance in

NIAID Data Ecosystem50

Inhibition of EB3 activates the Meis2-Pax6 regenerative program in wet AMD [scATAC-seq]

湿性年龄相关性黄斑变性治疗

染色质可及性分析

Wet age-related macular degeneration (AMD), characterized by leaky neovessels emanating from the choroid, is a main cause of blindness. As current treatments for wet AMD require regular intravitreal i

NIAID Data Ecosystem40

Inhibition of EB3 activates the Meis2-Pax6 regenerative program in wet AMD [scRNA-seq]. Inhibition of EB3 activates the Meis2-Pax6 regenerative program in wet AMD [scRNA-seq]

湿性年龄相关性黄斑变性治疗

组织再生

NIAID Data Ecosystem60

Shows the baseline characteristics and visual outcomes in the overall, bevacizumab and ranibizumab group.

抗VEGF药物

眼科研究

Shows the baseline characteristics and visual outcomes in the overall, bevacizumab and ranibizumab group.

NIAID Data Ecosystem50